ICE vs LCTX · P/E 37, rev $12.64B vs rev $9.5M
Intercontinental Exchange Inc (ICE) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Intercontinental Exchange Inc (ICE) is a financial data & stock exchanges company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported ICE revenue for 2025-12-31 was $12.64B. Net income was $3.31B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. ICE currently screens at market cap $103.55B and trailing P/E 37.3.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
ICE currently screens at market cap $103.55B and trailing P/E 37.3. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the ICE and LCTX stock pages for the full models.
Not investment advice.